NMNH Supplements in 2026: Evidence

NMNH is the reduced form of NMN and NAD+ precursors and looks more potent than NMN in cells and mice, but human evidence is still early. A completed industry-sponsored trial in 80 adults (NCT06889740) evaluated safety and pharmacokinetics; full published results are pending. If you want to experiment, choose a transparent product and keep expectations realistic: lab potency does not guarantee real-world benefits.

1. What Is NMNH?

NMNH (dihydronicotinamide mononucleotide) is a reduced form of nicotinamide mononucleotide. In the NAD+ biosynthetic pathway, NMN is normally converted into NAD+ by NMNAT enzymes. NMNH appears to bypass some rate-limiting steps more efficiently, producing larger and faster rises in intracellular NAD+ in preclinical models.

The compound first drew serious attention after a 2021 study in the FASEB Journal reported that NMNH was a "new and potent NAD+ precursor in mammalian cells and mice." Researchers found that NMNH raised NAD+ more effectively than NMN in several cell lines and increased liver NAD+ when given orally to mice.

2. The 2021 Breakthrough Study

Zapata-Pérez and colleagues showed that:

• NMNH raised NAD+ levels faster than NMN in cultured human and mouse cells.
• Oral NMNH increased NAD+ in mouse liver and some other tissues.
• The effect was dose-dependent and could be blocked by inhibitors of the NAD+ salvage pathway.

This was enough to make NMNH the most-talked-about next-generation NAD+ precursor. However, the study did not measure lifespan, disease endpoints or long-term safety in animals, and no human data were included.

3. Human Evidence: Where Are We in 2026?

Human NMNH research is growing but still limited:

• UthPeak NMNH trial (NCT06889740): A randomised, double-blind, placebo-controlled study in 80 healthy adults evaluating safety, tolerability and pharmacokinetics. It was completed but full peer-reviewed results are not yet widely available as of mid-2026.
• Pharmacokinetic studies: Early abstracts and conference presentations suggest NMNH is orally bioavailable and raises blood NAD+ metabolites, but detailed head-to-head comparisons with NMN are still sparse.
• Outcome data: No published human trial has yet tested whether NMNH improves physical performance, metabolic markers, vascular health or lifespan.

A 2026 review in Nature Metabolism of NAD+ precursor supplementation in human ageing concluded that evidence for meaningful clinical benefits in healthy adults remains mixed across all precursors, not just NMNH.

4. Product Review: Welzo NMNH Advanced NAD+ Formula 500mg

Welzo's NMNH product is one of the few-listed options that clearly discloses a 500mg dose of reduced-form NMNH per capsule. It is marketed as an "Advanced NAD+ Formula" and sold via Amazon.

Product details:

• Transparent 500mg NMNH dose per serving.
• Simple, single-ingredient formula.
• delivery with Amazon Prime and standard returns.
• Good customer rating and review volume.

Caveats:

• Human outcome data for NMNH are still limited.
• Long-term safety at 500mg/day has not been established.
• Marketing claims of being "4x stronger" refer to cell and mouse studies, not proven human effects.

5. Study Doses and Safety

Most NMNH supplements, including Welzo's, provide 500mg per capsule. Human dose-response data are still emerging, so published safety data are limited. This is product information, not a recommendation to exceed the labelled serving.

Combining NMNH with other NAD+ precursors (NMN, NR, niacin) is not supported by evidence and may increase the risk of exceeding studied doses; consult a clinician.

6. NMNH vs NMN vs NR

For evidences, the choice should be driven by risk tolerance and curiosity, not by certainty. NMNH is the newest and least-tested option. NMN and NR have more human data but are still not proven longevity interventions.

7. Key Studies

8. FAQ